Awakn Life Sciences Corp.: Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program

Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine
Toronto, Ontario--(Newsfile Corp. - August 25, 2022) - Awakn Life Sciences Corp. (NEO: AWKN)

Related Keywords

United Kingdom ,United States ,Canada ,Toronto ,Ontario ,America ,Gordo Whittaker ,Anne Donohoe ,Tesfa Mekonen ,Anthony Tennyson ,Linkedin Facebook ,Awakn Life Sciences ,Strategic Communications ,Newsfile Corp ,Awakn Life Sciences Corp ,Agreement Provides ,Month Exclusive Period ,Licensing Deal ,Proprietary Formulation ,Life Sciences ,Alcohol Use Disorder ,Project Kestrel ,Awakn Life ,United States Securities Act ,Global Burden ,Alcohol Use Disorders ,Alcohol Liver ,Awakn ,Life ,Ciences ,Orp ,Signs ,Agreement ,Reading ,Drug ,Development ,Company ,Eepen ,Boat ,Head ,Program ,